Xenetic Biosciences Inc (XBIO) Stock Price, Quote & News

Company Profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carc...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 778 7720

Website: www.xeneticbio.com

Address:

945 Concord Street, Framingham, United States

TJBUCK Oct. 24 at 12:36 AM

$XBIO whatever happened with the offering of 735k shares at 6.12 expected to close on 10/14?

0 · Reply

jjrrjjrr Oct. 23 at 3:43 PM

$MGRX $MGNX $DSY $XBIO NFA

0 · Reply

b3akohe Oct. 21 at 3:32 PM

$XBIO this one is clearly waking up. It has a huge potential. Watching very closely. Can get parabolic

0 · Reply

Slitherin Oct. 21 at 9:27 AM

PLRZ is the best biotech squeezer. $15M cash and no debt. Cash to fund operations for the next 50 months with no dilution. Very early hear and expecting news soon. $BYND $OPEN $ATMV $GLTO $XBIO worth watching as well

1 · Reply

SidneyRittinger147 Oct. 17 at 3:36 PM

$XBIO innovating biotech while AITX drives record-breaking AI adoption — one of its strongest multi-client single-day order totals yet shows momentum is real.

0 · Reply

AZOZ Oct. 17 at 11:45 AM

$XBIO Oversold swing idea!

0 · Reply

Goldwave9 Oct. 13 at 12:35 PM

$COCH $XBIO $MSS $WLDS $SOPA these are the "dogs I'm going with:) any movement will be meaningless until the IWM and QQQ reverse . Hopefully as early as tomorrow. Although we might see signs later today.

0 · Reply

BdGtradeR Oct. 13 at 9:55 AM

$XBIO we retake a position today - tomorrow

0 · Reply

Paraboljoker Oct. 13 at 9:52 AM

$PMAX Did you miss this lowfloat HongKong beast? Load up at $SUGP before the moass breakout!! 20% of float shortd 400k float! 🤌🏼💎🇭🇰 New $SPRB $XBIO $INHD

0 · Reply

Paraboljoker Oct. 13 at 9:06 AM

$PMAX Did you miss this lowfloat HongKong beast? Load up at $SUGP before the moass breakout!! 20% of float shortd 400k float! 🤌🏼💎🇭🇰 New $SPRB $XBIO

0 · Reply

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Aug 13, 2025, 8:00 AM EDT - 2 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 9:00 AM EDT - 3 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 23, 2025, 8:30 AM EDT - 3 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Jul 8, 2025, 9:00 AM EDT - 3 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

May 14, 2025, 8:05 AM EDT - 5 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 9, 2025, 9:15 AM EDT - 7 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

$Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma$

Mar 26, 2025, 9:00 AM EDT - 7 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Mar 19, 2025, 8:05 AM EDT - 7 months ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Mar 13, 2025, 8:30 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Feb 27, 2025, 9:15 AM EST - 8 months ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Dec 16, 2024, 9:00 AM EST - 11 months ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 5, 2024, 8:45 AM EST - 11 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Nov 21, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 13, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Oct 22, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Jan 17, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Nov 10, 2023, 8:35 AM EST - 2 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Oct 11, 2023, 9:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Sep 5, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 11, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Jul 5, 2023, 8:45 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

May 12, 2023, 12:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 11, 2023, 4:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

May 3, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Mar 23, 2023, 7:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

Mar 16, 2023, 11:00 AM EDT - 2 years ago

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Mar 16, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Jan 17, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Jan 5, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Nov 16, 2022, 8:35 AM EST - 3 years ago

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Nov 10, 2022, 7:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 11, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

VNRX

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Sep 7, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 12, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

VNRX

Jul 7, 2022, 9:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

Jun 2, 2022, 2:00 PM EDT - 3 years ago

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

Jun 2, 2022, 8:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

May 18, 2022, 8:15 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

TJBUCK Oct. 24 at 12:36 AM

$XBIO whatever happened with the offering of 735k shares at 6.12 expected to close on 10/14?

0 · Reply

jjrrjjrr Oct. 23 at 3:43 PM

$MGRX $MGNX $DSY $XBIO NFA

0 · Reply

b3akohe Oct. 21 at 3:32 PM

$XBIO this one is clearly waking up. It has a huge potential. Watching very closely. Can get parabolic

0 · Reply

Slitherin Oct. 21 at 9:27 AM

1 · Reply

SidneyRittinger147 Oct. 17 at 3:36 PM

$XBIO innovating biotech while AITX drives record-breaking AI adoption — one of its strongest multi-client single-day order totals yet shows momentum is real.

0 · Reply

AZOZ Oct. 17 at 11:45 AM

$XBIO Oversold swing idea!

0 · Reply

Goldwave9 Oct. 13 at 12:35 PM

0 · Reply

BdGtradeR Oct. 13 at 9:55 AM

$XBIO we retake a position today - tomorrow

0 · Reply

Paraboljoker Oct. 13 at 9:52 AM

$PMAX Did you miss this lowfloat HongKong beast? Load up at $SUGP before the moass breakout!! 20% of float shortd 400k float! 🤌🏼💎🇭🇰 New $SPRB $XBIO $INHD

0 · Reply

Paraboljoker Oct. 13 at 9:06 AM

$PMAX Did you miss this lowfloat HongKong beast? Load up at $SUGP before the moass breakout!! 20% of float shortd 400k float! 🤌🏼💎🇭🇰 New $SPRB $XBIO

0 · Reply

Paraboljoker Oct. 13 at 8:48 AM

$PMAX Did you miss this lowfloat HongKong beast? Load up at $SUGP before the moass breakout!! 20% of float shortd 400k float! New $SPRB $XBIO

0 · Reply

MilsLearning Oct. 13 at 7:42 AM

$XBIO "L"ets "F" "S"horts 🖕🩳🔥🩳🔥🖕🔜🕖✅ Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***

0 · Reply

StockChiefs Oct. 12 at 9:37 PM

Incase you guys missed the 900% GLTO run (1.2 mil float), Make sure add MTEX to your squeeze wathclists! Very nice after hours breakout - good momentum. Only 600k shares float. Holding some shares for a pre-market continuation run MTEX recently ran +100% in After-Hours and now it is breaking out again ! Keep it on watch bulls! $XBIO $JFU $NVX $CIIT ```

0 · Reply

GluttonBoy Oct. 12 at 7:57 PM

QTTB stock is the biotech stock to 5X Cash into 2027 with top line results coming soon. $15 PT by Wells Fargo. Low floater with no dilution and shorts trapped. Over 10% short interest and no shares left to borrow, a sleep giant ! $MTEK $OPEN $GLTO $XBIO Will keep an eye on these too

0 · Reply

Goldwave9 Oct. 11 at 1:58 PM

$COCH $XBIO $MSS $APVO $RELI so if all of these monsters are ready to reverse, why aren't they reversing? Answer: the market is not ready to reverse! QQQ and IWM look like they have a bit more downside. This could change in a day, but until then there's really nothing we can do.

4 · Reply

Btolz Oct. 10 at 8:39 PM

$XBIO this will recover Monday

0 · Reply

Slitherin Oct. 10 at 6:55 PM

QTTB highest shorted biotech nano float that has no dilution. Data due soon and cash to last them the next 2 years. Chart looks like a historic move is taking pls r and this was a $50+ stock one year ago. $GLTO $XBIO $SPRB $PCSA $BAOS WW too other biotechs

0 · Reply

Goldwave9 Oct. 10 at 4:38 PM

$XBIO Starter position, but holding some money back because I do believe it could go a bit lower here

0 · Reply

MilsLearning Oct. 10 at 4:30 PM

$XBIO Ever get bullied??? Trading stocks?? Me too!!! Well 🔥🖕🔥🖕🩳🩳🩳🔥

0 · Reply

Gianni85_ Oct. 10 at 3:39 PM

$XBIO potential bullish reversal

0 · Reply

_www_larval_com_ Oct. 10 at 3:07 PM

$XBIO just slipped -10% lower to -28% (~569Kv) a few minutes ago, follow for more volatility.

0 · Reply

Luckyluckalwys Oct. 10 at 2:55 PM

$XBIO don’t be fool by them why the heck people coming from everywhere posting all this bear shit. Lol 🤣. 50 plus PT. save my msg. 🚀🚀🚀

0 · Reply

Market Cap	5.95M
Revenue (ttm)	2.50M
Net Income (ttm)	-3.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-158.40%
Debt to Equity Ratio	0.00

Volume	80,200
Avg Vol	1,032,236
Day's Range	N/A - N/A
Shares Out	1.54M
Stochastic %K	19%
Beta	2.42
Analysts	Hold
Price Target	$40.00